Compare Hershey Co (HSY) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hershey Co vs Incyte Corporation — how do they compare? Hershey Co trades at $162.74 (market cap $32.66B), while Incyte Corporation trades at $112.79 (market cap $22.85B). The key difference: Hershey Co is the larger of the two by market cap, and Hershey Co pays a 3.57% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hershey Co for 135 Days and Incyte Corporation for 33 Days on average.
| HSY | INCY | |
|---|---|---|
Market Cap | $32.66B | $22.85B |
Volume | 1,578,237 | 1,927,029 |
Sector | Consumer Staples | Health |
52-Week High | $236.28 | $129.93 |
52-Week Low | $157.61 | $83.80 |
Typical Hold Time | 135 Days | 33 Days |
Enterprise Value | $37.79B | $18.35B |
Dividend Yield | 3.57% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hershey (HSY) trades at $162.54, up 1.37% with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with 12.24% net margin and 32.81% ROE, though 2025 net income declined to $883M. Analyst consensus targets $204.62 with 65.72% hold ratings, while recent news highlights dividend resumption and international leadership changes.
HSY offers value near 52-week lows with 25% upside to consensus target, supported by consistent earnings outperformance and brand strength. Key risks include cocoa cost pressures, margin compression from 2025 results, and technical bearish momentum. The dividend yield of 3.57% provides income support during market volatility.
Incyte (INCY) trades at $112.75, down 0.61% on the day, with a bearish technical signal despite strong fundamentals. The company reported robust 2025 results with $5.14B revenue and $1.29B net income, showing significant margin expansion. Recent FDA approval for Atebrioz and pipeline progress support growth prospects beyond JAKAFI's 2029 exclusivity loss. Analyst consensus is bullish with a $132.43 price target, though technical indicators show selling pressure near key resistance.
Outlook remains positive driven by pipeline diversification and operational leverage, but near-term technical weakness and reliance on JAKAFI transition pose risks. The stock offers value with a 14.36 P/E ratio and strong profitability metrics, though investors should monitor execution on the $4B non-JAKAFI sales target and quarterly earnings consistency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hershey Co
Hershey is a leading confectionery manufacturer in the U.S. (around a $25 billion market), controlling around 46% of the domestic chocolate space (per IRI). Beyond its namesake label, the firm's mix has expanded over the last 85 years and now consists of 100 brands, including Reese's, Kit Kat, Kisses, and Ice Breakers. Hershey's products are sold in about 80 countries, albeit with just a high-single-digit percentage of sales coming from markets outside the U.S., including Brazil, India, and Mexico. The firm has sought inorganic opportunities to extend its reach beyond its core confection business, adding Amplify Snack Brands and its Skinny Pop ready-to-eat popcorn to its mix and Pirate Brands (including the Pirate's Booty, Smart Puffs, and Original Tings brands) over the past few years.
Read more on HSY →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
